HCV Combo Therapy Demonstrates Antiviral Activity in Hard-to-Cure Patients

Positive results have been reported from the ongoing C-WORTHy study, a phase II clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor , in patients with chronic HCV ... (more)

http://ift.tt/1gvL16D